Liquidia Corporation

Liquidia Corporation makes Yutrepia (inhaled treprostinil for pulmonary arterial hypertension), which recently launched commercially and is showing rapid uptake against United Therapeutics' Tyvaso franchise. The stock is up 156% YTD but the '327 patent decision looming is the specific binary catalyst that decides the near-term move.

• The Yutrepia commercial launch is exceptional: Q1 revenue $133M up 4,159% YoY (essentially from zero) — this is the specific evidence the launch is landing at scale, and the FY26 revenue consensus of $725M growing to $1.18B FY27 reflects real commercialization.
• The margins are pharmaceutical-tier: gross margin 92%, operating margin 46% — Yutrepia is a high-value inhaled therapy that produces the exact economics specialty pharma investors want.
• The '327 patent decision is the load-bearing binary: PAH market alone is worth $6-8B (5-7x multiplier) if Liquidia wins the patent case, and Needham $110 and Wells Fargo $108 targets are underwriting that outcome — the specific $120-150 upside if LQDA wins framing is coherent.
• Insider tape has meaningful selling into the run: director Rielly-Gauvin sold ~$4M in two transactions on 8/21, and CMO Rajeev Saggar sold ~29K shares at $76.84 previously — insider selling ahead of a binary patent decision is worth flagging, though director selling is common at these levels.

The '327 patent decision is the specific catalyst — a favorable outcome unlocks the $120-150 range bulls target; an unfavorable outcome sends this back to the mid-$40s and materially impairs the FY27 revenue trajectory. Invalidator: an unfavorable '327 ruling, a Yutrepia commercial-launch stall, or a manufacturing issue. The heavy put buying on the 9/4 $55 strike shows options-market positioning for a negative outcome; the setup is genuinely binary and position sizing is more of the risk than direction.